Business, energy, technology, markets and global industry news from Business News Today

diabetes

PharmaDeviceNews diabetes
Medical Devices & Diagnostics

Modular Medical wins FDA clearance for Pivot insulin pump software enhancements

Pivot has FDA-cleared software upgrades and national PBM access. Modular Medical now has to prove that simpler insulin delivery converts users.

Read More
Representative image of a physician reviewing glucose trend data with a diabetes patient, reflecting Cirius Therapeutics’ CIR-0602K research and the growing search for new insulin-sensitizing therapies beyond GLP-1 drugs.
Pharma & Biotech

Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Read More
Representative image: Eli Lilly’s expanding diabetes and obesity drug pipeline, including Foundayo, Mounjaro and retatrutide, highlights the growing race to reshape cardiometabolic care through oral GLP-1 therapies, injectable incretin drugs and next-generation clinical trial advances.
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More
Lannett’s Lanexa Biologics enters U.S. insulin market with interchangeable LANGLARA approval
Pharma & Biotech

Could LANGLARA finally crack the high-cost insulin access problem in the United States?

Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.

Read More
Pharma & Biotech

Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?

Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.

Read More